salmeterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	2419	89365-50-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: serevent salmeterol salmeterol xinafoate	Salmeterol is a selective long acting beta2-adrenoceptor agonist. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness. It has received approval to be used in combination with fluticasone. Molecular weight: 415.57 Formula: C25H37NO4 CLOGP: 3.06 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 81.95 ALOGS: -5.26 ROTB: 16 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

serevent
salmeterol
salmeterol xinafoate

Salmeterol is a selective long acting beta2-adrenoceptor agonist. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness. It has received approval to be used in combination with fluticasone.

Molecular weight: 415.57
Formula: C25H37NO4
CLOGP: 3.06
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 81.95
ALOGS: -5.26
ROTB: 16

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	mg	Inhal.aerosol
0.10	mg	Inhal.powder

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
March 26, 2021	EMA	TEVA B.V.
Feb. 4, 1994	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	234.44	11.85	256	22207	127305	63339254
Chronic obstructive pulmonary disease	178.77	11.85	160	22303	62526	63404033
Dyspnoea	169.56	11.85	565	21898	660748	62805811
Eosinophilic granulomatosis with polyangiitis	130.48	11.85	43	22420	2149	63464410
Product quality issue	123.46	11.85	102	22361	35763	63430796
Chest discomfort	122.95	11.85	172	22291	109797	63356762
Wheezing	90.11	11.85	138	22325	95457	63371102
Ventilation perfusion mismatch	83.53	11.85	22	22441	496	63466063
Cough	76.13	11.85	252	22211	292491	63174068
Bronchitis	68.14	11.85	142	22321	124793	63341766
Dysphonia	66.31	11.85	83	22380	47531	63419028
Pneumonia	62.86	11.85	323	22140	456444	63010115
Contraindicated product administered	61.29	11.85	4	22459	217644	63248915
Product complaint	58.32	11.85	43	22420	12766	63453793
Treatment failure	58.06	11.85	3	22460	199040	63267519
Off label use	57.53	11.85	94	22369	674368	62792191
Bronchospasm	55.01	11.85	47	22416	17233	63449326
Synovitis	51.00	11.85	4	22459	186914	63279645
Status asthmaticus	50.87	11.85	17	22446	887	63465672
Drug intolerance	44.63	11.85	27	22436	308634	63157925
Product use issue	40.06	11.85	14	22449	220506	63246053
Systemic lupus erythematosus	38.41	11.85	13	22450	208905	63257654
Completed suicide	37.37	11.85	4	22459	145669	63320890
Stress fracture	34.61	11.85	26	22437	7937	63458622
Laryngeal pain	32.22	11.85	20	22443	4478	63462081
Myocardial infarction	31.43	11.85	92	22371	99801	63366758
Increased upper airway secretion	30.62	11.85	18	22445	3654	63462905
Arthropathy	30.62	11.85	23	22440	234769	63231790
Abdominal discomfort	29.88	11.85	42	22421	320843	63145716
Throat irritation	29.49	11.85	50	22413	37597	63428962
Infusion related reaction	28.40	11.85	27	22436	245494	63221065
Glossodynia	28.22	11.85	14	22449	178862	63287697
Intentional product use issue	27.16	11.85	6	22457	127886	63338673
Product use in unapproved indication	26.80	11.85	15	22448	179065	63287494
Pericarditis	26.33	11.85	7	22456	131572	63334987
Dysmetropsia	25.88	11.85	6	22457	78	63466481
Chest pain	25.05	11.85	146	22317	215813	63250746
Rheumatoid arthritis	24.86	11.85	32	22431	253787	63212772
Joint swelling	24.83	11.85	49	22414	327617	63138942
Palpitations	24.82	11.85	92	22371	112678	63353881
Peripheral swelling	24.56	11.85	35	22428	265907	63200652
Erysipelas	24.14	11.85	21	22442	7884	63458675
Productive cough	23.62	11.85	62	22401	63146	63403413
International normalised ratio increased	23.23	11.85	51	22412	46374	63420185
Therapeutic product effect decreased	22.62	11.85	21	22442	193166	63273393
Cardiac failure congestive	22.55	11.85	78	22385	92355	63374204
Haemoptysis	22.29	11.85	38	22425	28688	63437871
Psoriatic arthropathy	22.26	11.85	3	22460	91517	63375042
Acute respiratory failure	22.14	11.85	42	22421	34443	63432116
Derealisation	21.96	11.85	10	22453	1198	63465361
Alopecia	21.87	11.85	55	22408	337481	63129078
Eczema impetiginous	21.56	11.85	4	22459	15	63466544
Anxiety	20.81	11.85	140	22323	217401	63249158
Middle insomnia	20.80	11.85	24	22439	12619	63453940
Toxicity to various agents	20.48	11.85	35	22428	247215	63219344
Respiratory failure	19.88	11.85	80	22383	101778	63364781
Varicella zoster oesophagitis	19.48	11.85	4	22459	28	63466531
Anaphylactic reaction	19.01	11.85	59	22404	66041	63400518
Varicella zoster gastritis	18.90	11.85	4	22459	33	63466526
Discomfort	18.66	11.85	19	22444	167355	63299204
Cortisol decreased	18.60	11.85	9	22454	1235	63465324
Fracture displacement	18.49	11.85	9	22454	1252	63465307
Musculoskeletal stiffness	18.35	11.85	23	22440	184595	63281964
Inhalation therapy	17.95	11.85	4	22459	43	63466516
Hypoxia	17.78	11.85	54	22409	59738	63406821
Impaired healing	17.78	11.85	7	22456	102535	63364024
Emotional distress	17.72	11.85	37	22426	32512	63434047
Candida infection	17.55	11.85	34	22429	28317	63438242
Calculus bladder	17.39	11.85	7	22456	620	63465939
Lung disorder	17.38	11.85	55	22408	62206	63404353
Peroneal nerve injury	17.25	11.85	4	22459	52	63466507
Neutropenia	17.19	11.85	22	22441	174983	63291576
Tremor	17.04	11.85	92	22371	132147	63334412
Granuloma	16.98	11.85	15	22448	5746	63460813
Intentional overdose	16.74	11.85	3	22460	74149	63392410
Emphysema	16.73	11.85	20	22443	10918	63455641
Ecchymosis	16.50	11.85	20	22443	11074	63455485
Investigation	16.44	11.85	9	22454	1596	63464963
Oedema peripheral	16.38	11.85	119	22344	189392	63277167
Drug abuse	16.23	11.85	3	22460	72515	63394044
Febrile neutropenia	16.22	11.85	11	22452	118438	63348121
Kounis syndrome	15.81	11.85	9	22454	1721	63464838
Hypercapnia	15.73	11.85	14	22449	5417	63461142
Oligohydramnios	15.70	11.85	15	22448	6351	63460208
Adrenal insufficiency	15.65	11.85	25	22438	17890	63448669
Rash	15.33	11.85	126	22337	560745	62905814
Nikolsky's sign	14.75	11.85	4	22459	101	63466458
Drug ineffective	14.74	11.85	271	22192	1044494	62422065
Hepatic enzyme increased	14.68	11.85	31	22432	202297	63264262
Pharyngeal oedema	14.62	11.85	21	22442	13700	63452859
Myoclonic dystonia	14.49	11.85	3	22460	22	63466537
Throat tightness	14.38	11.85	29	22434	24858	63441701
Uterine hypertonus	14.37	11.85	5	22458	295	63466264
Diarrhoea	13.66	11.85	175	22288	715191	62751368
Femur fracture	13.65	11.85	39	22424	41717	63424842
Urethral pain	13.41	11.85	5	22458	360	63466199
Choking	13.39	11.85	17	22446	9862	63456697
Cerebrovascular accident	13.14	11.85	74	22389	107950	63358609
Cholecystitis chronic	12.75	11.85	17	22446	10344	63456215
Wound	12.71	11.85	24	22439	163239	63303320
Irritable bowel syndrome	12.18	11.85	7	22456	82405	63384154

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	220.20	13.56	151	11552	42505	34902723
Chronic obstructive pulmonary disease	150.04	13.56	127	11576	48791	34896437
Dyspnoea	104.72	13.56	319	11384	376463	34568765
Eosinophilic granulomatosis with polyangiitis	100.47	13.56	34	11669	1953	34943275
Cerebral artery thrombosis	75.82	13.56	22	11681	758	34944470
Brain scan abnormal	73.20	13.56	22	11681	858	34944370
Pneumonia	65.76	13.56	267	11436	362360	34582868
Wheezing	63.97	13.56	74	11629	41328	34903900
Product quality issue	51.67	13.56	44	11659	16991	34928237
Product complaint	50.96	13.56	29	11674	5861	34939367
Areflexia	49.82	13.56	23	11680	3008	34942220
Status asthmaticus	48.91	13.56	13	11690	322	34944906
Fractional exhaled nitric oxide increased	48.80	13.56	17	11686	1065	34944163
Toxicity to various agents	42.22	13.56	8	11695	200354	34744874
Plantar fasciitis	40.95	13.56	18	11685	2098	34943130
Sensation of foreign body	39.23	13.56	19	11684	2764	34942464
Myoglobin blood increased	31.98	13.56	17	11686	3006	34942222
Respiratory distress	30.78	13.56	48	11655	35617	34909611
Dysphonia	29.90	13.56	38	11665	23345	34921883
Brain natriuretic peptide increased	29.04	13.56	20	11683	5639	34939589
Hepatic cancer	28.47	13.56	23	11680	8252	34936976
Hemiplegia	27.48	13.56	21	11682	6951	34938277
Carcinoid tumour of the gastrointestinal tract	27.47	13.56	6	11697	62	34945166
Off label use	26.40	13.56	64	11639	419460	34525768
Cough	25.78	13.56	109	11594	150031	34795197
Facial paralysis	25.19	13.56	24	11679	10710	34934518
Respiratory failure	24.52	13.56	86	11617	108486	34836742
Obstructive airways disorder	24.42	13.56	28	11675	15466	34929762
Pneumothorax	24.37	13.56	31	11672	19061	34926167
Ischaemic stroke	23.87	13.56	30	11673	18220	34927008
Drug abuse	23.01	13.56	3	11700	99093	34846135
Exostosis	22.62	13.56	16	11687	4707	34940521
Eosinophilia	22.21	13.56	35	11668	26187	34919041
Sinusitis	21.89	13.56	45	11658	41357	34903871
Oral candidiasis	20.99	13.56	23	11680	12087	34933141
Benign prostatic hyperplasia	20.85	13.56	25	11678	14470	34930758
Coronary artery disease	20.44	13.56	48	11655	48257	34896971
Inhalation therapy	19.58	13.56	4	11699	29	34945199
Secretion discharge	19.44	13.56	16	11687	5889	34939339
Cardiac failure congestive	18.82	13.56	66	11637	83204	34862024
Cardiac disorder	17.32	13.56	42	11661	43084	34902144
Dyspnoea exertional	17.22	13.56	42	11661	43237	34901991
Carcinoid tumour of the stomach	17.13	13.56	4	11699	57	34945171
Atrial fibrillation	16.64	13.56	83	11620	122310	34822918
Increased upper airway secretion	15.89	13.56	9	11694	1801	34943427
Product use in unapproved indication	15.68	13.56	10	11693	117489	34827739
Lipohypertrophy	15.01	13.56	5	11698	273	34944955
Emphysema	14.65	13.56	17	11686	9508	34935720
Bronchospasm	14.61	13.56	18	11685	10713	34934515
Post streptococcal glomerulonephritis	14.22	13.56	4	11699	123	34945105
Febrile neutropenia	14.11	13.56	15	11688	136834	34808394
Pseudomonas infection	14.08	13.56	19	11684	12363	34932865
Bronchitis	13.89	13.56	38	11665	41925	34903303

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	273.59	11.92	277	26154	134818	79583139
Eosinophilic granulomatosis with polyangiitis	231.52	11.92	74	26357	3586	79714371
Chronic obstructive pulmonary disease	229.75	11.92	205	26226	85214	79632743
Dyspnoea	176.38	11.92	652	25779	856373	78861584
Product quality issue	119.07	11.92	95	26336	33845	79684112
Chest discomfort	97.86	11.92	169	26262	137875	79580082
Pneumonia	94.27	11.92	450	25981	659796	79058161
Wheezing	82.90	11.92	143	26288	116521	79601436
Ventilation perfusion mismatch	80.34	11.92	22	26409	618	79717339
Product complaint	68.52	11.92	47	26384	13302	79704655
Bronchitis	66.59	11.92	139	26292	130505	79587452
Brain scan abnormal	66.28	11.92	22	26409	1201	79716756
Cerebral artery thrombosis	64.29	11.92	21	26410	1090	79716867
Cough	61.90	11.92	263	26168	366526	79351431
Off label use	61.40	11.92	131	26300	907084	78810873
Status asthmaticus	57.64	11.92	19	26412	1015	79716942
Toxicity to various agents	53.76	11.92	37	26394	421503	79296454
Completed suicide	48.53	11.92	11	26420	245756	79472201
Treatment failure	41.97	11.92	4	26427	170482	79547475
Bronchospasm	41.37	11.92	46	26385	24813	79693144
Drug abuse	39.57	11.92	4	26427	162687	79555270
Intentional product use issue	36.32	11.92	4	26427	152108	79565849
Increased upper airway secretion	34.80	11.92	20	26411	4157	79713800
Areflexia	32.04	11.92	21	26410	5513	79712444
Product use in unapproved indication	31.85	11.92	22	26409	250337	79467620
Haemoptysis	31.37	11.92	62	26369	55937	79662020
COVID-19	31.23	11.92	7	26424	157667	79560290
Contraindicated product administered	31.19	11.92	7	26424	157531	79560426
Myocardial infarction	30.19	11.92	131	26300	183998	79533959
Drug intolerance	30.05	11.92	26	26405	264093	79453864
Respiratory failure	29.88	11.92	129	26302	180782	79537175
Cerebrovascular accident	29.81	11.92	116	26315	155176	79562781
Cardiac failure congestive	29.50	11.92	109	26322	142293	79575664
Febrile neutropenia	28.46	11.92	21	26410	230978	79486979
Hypoxia	28.45	11.92	87	26344	103156	79614801
Inhalation therapy	28.18	11.92	6	26425	55	79717902
Productive cough	27.76	11.92	78	26353	88253	79629704
Dysphonia	27.20	11.92	59	26372	56813	79661144
Tremor	25.61	11.92	118	26313	169965	79547992
Carcinoid tumour of the gastrointestinal tract	25.60	11.92	6	26425	88	79717869
Laryngeal pain	25.56	11.92	19	26412	6095	79711862
Dysmetropsia	25.41	11.92	6	26425	91	79717866
Oral candidiasis	24.62	11.92	39	26392	29589	79688368
Stress fracture	24.57	11.92	19	26412	6461	79711496
Erysipelas	23.28	11.92	23	26408	10827	79707130
Acute respiratory failure	23.22	11.92	57	26374	59484	79658473
International normalised ratio increased	22.98	11.92	71	26360	84650	79633307
Throat irritation	22.53	11.92	45	26386	40901	79677056
Palpitations	22.23	11.92	92	26339	126518	79591439
Rheumatoid arthritis	21.96	11.92	22	26409	208448	79509509
Respiratory distress	21.86	11.92	55	26376	58284	79659673
Chest pain	21.13	11.92	163	26268	282141	79435816
Product use issue	20.05	11.92	24	26407	209798	79508159
Pericarditis	19.90	11.92	5	26426	104231	79613726
Varicella zoster oesophagitis	19.74	11.92	4	26427	28	79717929
Cortisol decreased	19.71	11.92	11	26420	2161	79715796
Derealisation	19.62	11.92	10	26421	1639	79716318
Varicella zoster gastritis	19.16	11.92	4	26427	33	79717924
Emphysema	18.71	11.92	25	26406	16275	79701682
Fracture displacement	18.60	11.92	9	26422	1319	79716638
Intentional overdose	18.53	11.92	6	26425	105954	79612003
Infective pulmonary exacerbation of cystic fibrosis	18.39	11.92	22	26409	12829	79705128
Peripheral swelling	18.08	11.92	39	26392	269578	79448379
Facial paralysis	17.87	11.92	28	26403	21044	79696913
Middle insomnia	17.46	11.92	24	26407	16045	79701912
Hypercapnia	17.45	11.92	18	26413	8917	79709040
Peroneal nerve injury	16.98	11.92	4	26427	60	79717897
Benign prostatic hyperplasia	16.81	11.92	20	26411	11592	79706365
Infusion related reaction	16.54	11.92	32	26399	230205	79487752
Psoriatic arthropathy	16.40	11.92	3	26428	77996	79639961
Systemic lupus erythematosus	16.27	11.92	10	26421	121139	79596818
Diffuse panbronchiolitis	16.02	11.92	3	26428	13	79717944
Malignant neoplasm progression	15.93	11.92	13	26418	135977	79581980
Hemiplegia	15.77	11.92	22	26409	14917	79703040
Lipohypertrophy	15.51	11.92	7	26424	877	79717080
Calculus bladder	15.40	11.92	8	26423	1364	79716593
Joint swelling	15.31	11.92	47	26384	288599	79429358
Emotional distress	15.30	11.92	38	26393	39931	79678026
Lung disorder	15.30	11.92	60	26371	80497	79637460
Sinusitis	15.25	11.92	114	26317	195387	79522570
Uterine hypertonus	15.19	11.92	5	26426	266	79717691
Pulseless electrical activity	15.17	11.92	21	26410	14139	79703818
Anxiety	15.13	11.92	137	26294	248375	79469582
Hepatic cancer	15.02	11.92	18	26413	10511	79707446
Granuloma	14.93	11.92	16	26415	8281	79709676
Therapeutic product effect decreased	14.35	11.92	20	26411	163843	79554114
Hepatic enzyme increased	14.35	11.92	24	26407	182586	79535371
Post streptococcal glomerulonephritis	14.14	11.92	4	26427	127	79717830
Neutropenia	13.78	11.92	49	26382	287661	79430296
Impaired healing	13.60	11.92	6	26425	87649	79630308
Central obesity	13.53	11.92	8	26423	1753	79716204
Coronary artery disease	13.45	11.92	50	26381	65424	79652533
Arthropathy	13.26	11.92	24	26407	177087	79540870
Candida infection	13.25	11.92	35	26396	38179	79679778
Lung hyperinflation	13.13	11.92	8	26423	1851	79716106
Swelling face	12.69	11.92	52	26379	71160	79646797
Ecchymosis	12.61	11.92	20	26411	15186	79702771
Carcinoid tumour of the stomach	12.49	11.92	4	26427	195	79717762
Pulmonary function test decreased	12.48	11.92	14	26417	7623	79710334
Pulmonary embolism	12.22	11.92	98	26333	171556	79546401
Urethral pain	12.18	11.92	5	26426	497	79717460
Sputum discoloured	12.09	11.92	24	26407	21719	79696238
C-reactive protein increased	12.07	11.92	15	26416	129012	79588945
White blood cell count decreased	11.99	11.92	28	26403	188260	79529697
Spirometry abnormal	11.95	11.92	6	26425	953	79717004
Oedema peripheral	11.93	11.92	132	26299	252156	79465801

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R03AC12	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03AK06	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK12	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA MoA	N0000009922	Adrenergic beta2-Agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35523	bronchodilator
FDA EPC	N0000175779	beta2-Adrenergic Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pulmonary emphysema	indication	87433001
Non-allergic asthma	indication	266361008	DOID:9360
Allergic asthma	indication	389145006	DOID:9415
Adjunct Therapy to Achieve Long-term Asthma Control	indication
Bronchospasm Prevention with COPD	indication
Exercise-Induced Bronchospasm Prevention	indication
COPD Associated with Chronic Bronchitis	indication
Mycosis	contraindication	3218000	DOID:1564
Disease caused by parasite	contraindication	17322007
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Ketoacidosis	contraindication	56051008
Osteoporosis	contraindication	64859006	DOID:11476
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Candidiasis of mouth	contraindication	79740000	DOID:14262
Hyperglycemia	contraindication	80394007	DOID:4195
Thyrotoxicosis	contraindication	90739004	DOID:7997
Bilateral cataracts	contraindication	95722004
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Ophthalmic herpes simplex	contraindication	186542001
Exacerbation of asthma	contraindication	281239006
Osteopenia	contraindication	312894000
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Congenital long QT syndrome	contraindication	442917000
Uncontrolled Bacterial Infections	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.07	acidic
pKa2	9.28	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	9415008	Oct. 6, 2034	TREATMENT OF ASTHMA
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	9415008	Oct. 6, 2034	TREATMENT OF ASTHMA
0.113MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA
0.113MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA
0.232MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA
0.232MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	9066957	Oct. 6, 2034	TREATMENT OF ASTHMA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	July 9, 2024	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	July 9, 2024	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO DIGIHALER	TEVA PHARM	N208799	July 12, 2019	RX	POWDER	INHALATION	Jan. 9, 2025	PEDIATRIC EXCLUSIVITY
0.055MG/INH;EQ 0.014MG BASE/INH	AIRDUO RESPICLICK	TEVA PHARM	N208799	Jan. 27, 2017	RX	POWDER	INHALATION	Jan. 9, 2025	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Ki	9.41	CHEMBL	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	4.50	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.98	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.00	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		EC50	6	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	6.10	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		EC50	7.50	CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_MOUSE		Ki	6.26	CHEMBL

External reference:

ID	Source
4023955	VUID
N0000021960	NUI
D00687	KEGG_DRUG
94749-08-3	SECONDARY_CAS_RN
4020873	VANDF
4023955	VANDF
C0245531	UMLSCUI
CHEBI:9011	CHEBI
K5Y	PDB_CHEM_ID
CHEMBL1263	ChEMBL_ID
CHEMBL1082607	ChEMBL_ID
D000068299	MESH_DESCRIPTOR_UI
DB00938	DRUGBANK_ID
5152	PUBCHEM_CID
559	IUPHAR_LIGAND_ID
5578	INN_ID
2I4BC502BT	UNII
203159	RXNORM
1605	MMSL
21564	MMSL
5440	MMSL
d03759	MMSL
004036	NDDF
004037	NDDF
108605008	SNOMEDCT_US
108606009	SNOMEDCT_US
372515005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0326	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0326	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0327	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0327	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3607	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3607	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3607	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3608	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3608	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3608	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3609	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3609	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3609	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA authorized generic	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7516	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7516	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7517	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7517	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7518	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7518	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
SEREVENTDISKUS	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0520	POWDER, METERED	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
SEREVENTDISKUS	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0521	POWDER, METERED	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
SEREVENTDISKUS	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0521	POWDER, METERED	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0695	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0695	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0695	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0696	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0696	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0696	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0697	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0697	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections